Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase.
Microorganisms
; 9(5)2021 Apr 22.
Article
in English
| MEDLINE | ID: covidwho-1201125
ABSTRACT
Coronavirus Disease 2019 (COVID-19) is a deadly emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is easily transmitted through the air and has a relatively long incubation time, COVID-19 has rapidly developed into a global pandemic. As there are no antiviral agents for the prevention and treatment of this severe pathogen except for remdesivir, development of antiviral therapies to treat infected individuals remains highly urgent. Here, we showed that baicalein and baicalin exhibited significant antiviral activity against SARS-CoV-2, the causative agent of COVID-19 through in vitro studies. Our data through cell-based and biochemical studies showed that both compounds act as SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitors directly and inhibit the activity of the SARS-CoV-2 RdRp, but baicalein was more potent. We also showed specific binding of baicalein to the SARS-CoV-2 RdRp, making it a potential candidate for further studies towards therapeutic development for COVID-19 as a selective non-nucleoside polymerase inhibitor.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Long Covid
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Microorganisms9050893
Similar
MEDLINE
...
LILACS
LIS